Natixis Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Natixis Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Buy	+11,510	New	+$282K	﹤0.01%	1677

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Natixis Advisors's AMPH Position: Q1 2026 in Review

Natixis Advisors opened a new position in Amphastar Pharmaceuticals (AMPH) in Q1 2026: 11,510 shares worth $225K. The stake represents ﹤0.01% of the portfolio and ranks #1677 among its holdings.

215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

Natixis Advisors held 11,510 shares of Amphastar Pharmaceuticals worth $225K as of Q1 2026.
Amphastar Pharmaceuticals was a new Natixis Advisors position in Q1 2026.
Amphastar Pharmaceuticals made up ﹤0.01% of Natixis Advisors's portfolio in Q1 2026, its #1677 holding.
215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Natixis Advisors's 13F filing for Q1 2026, filed 13 May 2026.